Pierre Fabre Laboratories starts Phase I/II trial for MET-targeting NSCLC treatment PFL-002/VERT-002.

Pierre Fabre Laboratories has initiated a Phase I/II clinical trial for PFL-002/VERT-002, a monoclonal antibody aimed at treating non-small cell lung cancer (NSCLC) patients with MET alterations. The trial will evaluate the therapy's safety, tolerability, and preliminary effectiveness. PFL-002/VERT-002 works by degrading the c-MET oncogene, potentially offering a new treatment option for patients resistant to existing therapies.